Mumps orthorubulavirus antigens (MuV antigens) (MuV antigens)

Mumps orthorubulavirus antigens are the structural and non-structural proteins of the mumps virus that serve as the primary targets for the host immune system and diagnostic assays. The most significant therapeutic targets among these are the surface glycoproteins, hemagglutinin-neuraminidase (HN) and the fusion (F) protein, which facilitate viral attachment to sialic acid receptors and subsequent membrane fusion with the host cell (Source: StatPearls, 'Mumps'). The nucleoprotein (N) is also a major antigen used in diagnostic testing due to its high expression levels during viral replication (Source: UniProt, 'Nucleoprotein'). These antigens are the basis for live-attenuated vaccines, such as the Jeryl Lynn strain, which induce the production of neutralizing antibodies and T-cell responses to prevent infection (Source: CDC, 'Mumps Vaccination'). In clinical settings, the detection of these antigens or the host's immunological response to them (IgM/IgG) serves as the gold standard for diagnosing mumps infection and assessing vaccine efficacy (Source: Mayo Clinic Laboratories). While there are currently no widely approved antiviral drugs that specifically target these antigens, they remain the focus of research for developing monoclonal antibodies and novel therapeutics to manage outbreaks (Source: PubMed, PMID: 31433145). Understanding the antigenic variability of these proteins is crucial for monitoring vaccine effectiveness against emerging viral genotypes (Source: WHO, 'Mumps virus').

Other names

Mumps virus antigensMuV proteinsMumps virus proteinsParamyxovirus mumps antigens

Induction of active immunity through the production of neutralizing antibodies against viral surface glycoproteins and cell-mediated immune responses.